Stanozolol is an androgen, an anabolic steroid. Penetrating into the cell nucleus, stanozolol activates the genetic apparatus of the cell, which leads to an increase in the synthesis of DNA, RNA and structural proteins, activation of link enzymes and increased tissue respiration, oxidative phosphorylation, ATP synthesis and the accumulation of macroergs in the cell. It stimulates anabolic and suppresses catabolic processes caused by glucocorticoids. Improves tissue trophism, promotes the deposition of calcium in the bones, retains nitrogen, phosphorus, and sulfur in the body. The hematopoietic effect is associated with an increase in the synthesis of erythropoietin. The anti-allergic effect is due to an increase in the concentration of the C1 fraction of the complement. Androgen activity may contribute to the development of secondary sexual characteristics of the male type.
In complex therapy:
Prophylactic use to reduce the frequency and severity of attacks of hereditary angioedema.
Violation of protein synthesis, cachexia of various origins;
Injuries, burns, pre-and postoperative periods, recovery period after infectious diseases and radiation exposure;
Toxic goiter, muscular dystrophy, osteoporosis, negative nitrogen balance in corticosteroid therapy, hypo - and aplastic anemia.
- prostate cancer in men, breast cancer in women, breast carcinoma in women with hypercalcemia;
- coronary heart disease, atherosclerosis;
- liver and kidney failure;
- acute and chronic prostatitis;
- the period of pregnancy and lactation;
- children's age.
Pregnancy and breastfeeding
The category of action on the fetus according to the FDA is X.
The use of anabolic steroids, especially in the first trimester of pregnancy, can cause virilization of the external genitalia in a female fetus.
Use during pregnancy is contraindicated.
Reversible oligospermia may occur after prolonged use or excessive dosage. In the event of such an effect, the use of an anabolic steroid can be discontinued, and a lower dosage should be used when taking it again.
Method of administration and dosage
Similar to other steroids. Hepatotoxic (in oral and injectable forms), has a negative effect on the prostate. May contribute to hair loss and the appearance of acne (acne). The drug slightly suppresses the production of endogenous testosterone and does not lead to the occurrence of gynecomastia. In women, it can lead to pronounced virilization. Stanozolol can also lead to high blood pressure, it increases the amount of " bad " cholesterol (which can lead to coronary heart disease). According to the manufacturer of stanozolol (strombafort), its use can cause in women the suppression of ovarian function, menstrual disorders, hypercalcemia. In men: prepubertal period-symptoms of virilization, idiopathic hyperpigmentation of the skin, slowing or stopping growth (calcification of the growth zones of the tubular bones), in the post-pubertal period-irritation of the bladder, gynecomastia, priapism; in the elderly - hypertrophy and/or carcinoma of the prostate gland. Other side effects according to the manufacturer's data include the progression of atherosclerosis, peripheral edema, dyspeptic disorders, liver function disorders with jaundice, changes in the white blood cell formula, pain in the long tubular bones, hypocoagulation with a tendency to bleeding.
|Active ingredient, mg||50|
|1 bottle, ml||10|
|Bottles in the package, pcs||1|
|Manufacturer||CYGNUS pharmaceuticals group|